Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
21 Juin 2023 - 12:09PM
Edgar (US Regulatory)
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
REPORT
OF FOREIGN PRIVATE ISSUER
PURSUANT
TO RULE 13a-16 OR 15d-163
UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For
the month of June 2023
Alterity
Therapeutics Limited
(Name
of Registrant)
Level
3, 460 Bourke Street, Melbourne, VIC 3000, Australia
(Address
of Principal Executive Office)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
This
Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073,
333-248980 and 333-228671)
and our Registration Statements on Form F-3 (Files No. 333-251647,
333-249311, 333-231417
and 333-250076)
ALTERITY
THERAPEUTICS LIMITED
(a
development stage enterprise)
The
following exhibits are submitted:
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
|
Alterity Therapeutics Limited |
|
|
|
/s/ Geoffrey P. Kempler |
|
By: |
Geoffrey P. Kempler |
|
|
Chairman |
Date:
June 21, 2023
2
Alterity Therapeutics (PK) (USOTC:PRNAF)
Graphique Historique de l'Action
De Fév 2025 à Mar 2025
Alterity Therapeutics (PK) (USOTC:PRNAF)
Graphique Historique de l'Action
De Mar 2024 à Mar 2025
Real-Time news about Alterity Therapeutics Ltd (PK) (OTCMarkets): 0 recent articles
Plus d'articles sur Alterity Therapeutics Ltd